Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma
Sponsored by Peking University
About this trial
Last updated 5 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Started 14 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- patients with confirmed pathological diagnosis of ENKTL as defined by WHO criteria
- age 14-80 years
- no prior chemotherapy or radiotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- at least one measurable lesion
- adequate bone marrow function (i.e. hemoglobin ≥80 g/l, absolute neutrophil count ≥ 1.0 × 10^9/L, platelets ≥ 100 ×10^9/L), adequate renal function (i.e. serum creatinine ≤177 μmol/L), adequate hepatic function (e.g. total bilirubin ≤ two times the upper limit of normal, and ALT /AST ≤2.5 times the upper limit of normal)
- expected survival of more than three months
Exclusion Criteria
- invasion of lymphoma to central nervous system
- pre-existing coagulation disorder
- other concomitant neoplasms
- severe infection
- positive HIV antibody
- HBV DNA titer higher than 10^4 copies /ml in HBsAg-positive patients post antiviral therapy
- pregnant or lactating women
- women of childbearing age unwilling to take contraceptive measures during the study period